Here are five things to know about the process, according to an Oct. 3 news release from CMS:
- Abbott formally requested the national coverage analysis in a 2023 letter.
- Transcatheter edge-to-edge repair (TEER) is used to treat mitral regurgitation. T-TEER applies similar technology to the treatment of tricuspid valve regurgitation.
- CMS is soliciting public comment, including scientific evidence and peer-reviewed literature, as part of the coverage analysis.
- The public comment period ends Nov. 2.
- CMS expects to complete its analysis by July 2.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
